Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$295K Buy
2,450
+500
+26% +$57.7K 0.06% 100
2025
Q4
$205K Buy
1,950
+186
+11% +$17.5K 0.04% 124
2025
Q3
$148K Buy
1,764
+319
+22% +$26.3K 0.03% 143
2025
Q2
$114K Buy
1,445
+591
+69% +$47K 0.03% 156
2025
Q1
$76.6K Buy
854
+412
+93% +$38.5K 0.02% 177
2024
Q4
$43.9K Sell
442
-29
-6% -$2.99K 0.01% 218
2024
Q3
$53.5K Buy
471
+142
+43% +$16.9K 0.01% 196
2024
Q2
$40.8K Buy
329
+63
+24% +$8.12K 0.01% 205
2024
Q1
$35.1K Sell
266
-1,458
-85% -$180K 0.01% 227
2023
Q4
$188K Buy
+1,724
New +$179K 0.05% 140

Other funds holding MRK

REAP Financial Group's MRK Position: Q1 2026 in Review

REAP Financial Group increased its Merck (MRK) stake by 26% in Q1 2026, buying an estimated $57.7K and bringing the position to 2,450 shares worth $295K. The position accounts for 0.06% of the portfolio, ranked #100.

REAP Financial Group first reported a position in MRK in Q4 2023 and has held it in 10 quarters since. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • REAP Financial Group held 2,450 shares of Merck worth $295K as of Q1 2026.
  • REAP Financial Group bought 500 Merck shares in Q1 2026, an estimated $57.7K.
  • Merck made up 0.06% of REAP Financial Group's portfolio in Q1 2026, its #100 holding.
  • REAP Financial Group first reported a position in Merck in Q4 2023 and has held it in 10 quarters since.
  • 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on REAP Financial Group's 13F filing for Q1 2026, filed 11 May 2026.